PE20080053A1 - Composiciones oftalmicas de alcaftadina - Google Patents

Composiciones oftalmicas de alcaftadina

Info

Publication number
PE20080053A1
PE20080053A1 PE2007000398A PE2007000398A PE20080053A1 PE 20080053 A1 PE20080053 A1 PE 20080053A1 PE 2007000398 A PE2007000398 A PE 2007000398A PE 2007000398 A PE2007000398 A PE 2007000398A PE 20080053 A1 PE20080053 A1 PE 20080053A1
Authority
PE
Peru
Prior art keywords
alcaftadine
ophthalmic compositions
eye
ophthalmic
imidaze
Prior art date
Application number
PE2007000398A
Other languages
English (en)
Inventor
Jagdish Parasrampuria
Avner Ingerman
Frans Janssens
Anton Megens
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of PE20080053A1 publication Critical patent/PE20080053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION OFTALMICA QUE COMPRENDE DE 0,005% A 10% POR PESO DE ALCAFTADINA (6,11-DIHIDRO-11-(1-METIL-4-PIPERIDINILIDENO)-5H-IMIDAZO[2,1-b][3]BENZAZEPINA-3-CARBOXALDEHIDO) Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. DICHA FORMULACION SE PRESENTA BAJO LA FORMA DE SOLUCION O SUSPENSION OFTALMICA Y ES UTIL EN EL TRATAMIENTO DE ENROJECIMIENTO OCULAR, PICAZON OCULAR, HINCHAZON DE PARPADOS, QUEMOSIS, ENTRE OTRAS
PE2007000398A 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina PE20080053A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
PE20080053A1 true PE20080053A1 (es) 2008-03-10

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000398A PE20080053A1 (es) 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina

Country Status (30)

Country Link
US (7) US8664215B2 (es)
EP (2) EP3150209B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK3150209T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2594655T3 (es)
HK (1) HK1131331A1 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL2004196T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI450721B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648115C (en) 2006-03-31 2015-03-24 Vistakon Pharmaceuticals, Llc Ocular allergy treatments
JP2009535342A (ja) 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
JP2011503061A (ja) * 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
ES2910374T3 (es) 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2019026992A1 (ja) * 2017-08-03 2019-02-07 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
MA51612B1 (fr) * 2018-01-18 2021-06-30 Faes Farma Sa Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant
BR112022024840A2 (pt) 2020-06-15 2022-12-27 Alkem Laboratories Ltd Combinação de alcaftadina e um corticosteroide
AU2021437358A1 (en) 2021-04-01 2023-09-14 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
TW202408472A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
CA2093797C (en) * 1990-10-10 1998-09-22 Richard J. Friary Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CA2908828C (en) 2006-03-17 2018-01-16 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
CA2648115C (en) 2006-03-31 2015-03-24 Vistakon Pharmaceuticals, Llc Ocular allergy treatments

Also Published As

Publication number Publication date
US20230181594A1 (en) 2023-06-15
US20140107102A1 (en) 2014-04-17
TWI450721B (zh) 2014-09-01
JO3358B1 (ar) 2019-03-13
JP2015131820A (ja) 2015-07-23
PL2004196T3 (pl) 2017-01-31
WO2007117971A2 (en) 2007-10-18
CL2007000916A1 (es) 2008-01-25
KR101321731B1 (ko) 2013-10-30
NZ571690A (en) 2011-09-30
JP5292277B2 (ja) 2013-09-18
TW200815016A (en) 2008-04-01
MY153669A (en) 2015-03-13
SG170044A1 (en) 2011-04-29
EA200870396A1 (ru) 2009-04-28
DK3150209T3 (da) 2019-10-28
US20120094978A1 (en) 2012-04-19
JP6039716B2 (ja) 2016-12-07
UY30254A1 (es) 2007-08-31
US20240058355A1 (en) 2024-02-22
JP2009533333A (ja) 2009-09-17
ES2752823T3 (es) 2020-04-06
JP2013144703A (ja) 2013-07-25
CN102895234A (zh) 2013-01-30
WO2007117971A3 (en) 2007-12-27
NO20084593L (no) 2008-10-29
AU2007234957A1 (en) 2007-10-18
ECSP088786A (es) 2009-01-30
PL3150209T3 (pl) 2020-03-31
US10617695B2 (en) 2020-04-14
DK2004196T3 (en) 2016-09-05
EP3150209B1 (en) 2019-07-24
BRPI0710085A2 (pt) 2011-08-23
IL194473A (en) 2016-04-21
MX2008012657A (es) 2009-02-19
CA2648115C (en) 2015-03-24
EP2004196B1 (en) 2016-06-29
EA016221B1 (ru) 2012-03-30
US8664215B2 (en) 2014-03-04
AU2007234957B2 (en) 2012-12-13
BRPI0710085B8 (pt) 2021-05-25
TWI578990B (zh) 2017-04-21
NI200800261A (es) 2012-10-30
BRPI0710085B1 (pt) 2019-12-17
EP2004196A2 (en) 2008-12-24
IL194473A0 (en) 2009-08-03
CA2648115A1 (en) 2007-10-18
TW201446249A (zh) 2014-12-16
US20080051385A1 (en) 2008-02-28
EP3150209A1 (en) 2017-04-05
NO341147B1 (no) 2017-09-04
CR10414A (es) 2009-02-23
US20170065605A1 (en) 2017-03-09
KR20080110881A (ko) 2008-12-19
ES2594655T3 (es) 2016-12-21
AR060278A1 (es) 2008-06-04
ZA200809327B (en) 2009-12-30
HK1131331A1 (en) 2010-01-22
US20210030762A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
BRPI0512569A (pt) métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
MA31953B1 (fr) Nouveaux derives du thiophene.
PE20110287A1 (es) Composiciones oftalmicas que comprenden riboflavina en combinacion con la asociacion de edta y trometamina, o en combinacion con fotointensificadores
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
CL2007003821A1 (es) Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras.
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
CL2007001178A1 (es) Compuestos fusionados derivados de tetrahidro[1,2,4]triazol[4,3-a]pirimidina, moduladores de receptores de glutamato metabotropicos (mglur5); compuestos intermediarios; composicion y combinacion farmaceutica que los comprende; y su uso en la preparacion de medicamentos para tratar enfermedades gastroesofagicas, la ansiedad y dolores.
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
UY31430A1 (es) Derivados de piridina y pirazina -83
CR9232A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
RU2012103538A (ru) Композиции и способы ингибирования пути jak
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
ECSP066808A (es) Solución oftálmica que comprende carboximetilcelulosa de sodio e hidroxipropilmetilcelulosa
GT200900173A (es) Dispersión sólida de un antagonista de neuroquinina
MX2010000130A (es) Derivados de 3-espiropirimidintriona-quinolina y su uso como agentes antibacterianos.
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Legal Events

Date Code Title Description
FG Grant, registration